Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Dermatologic 1

Conditions

Melanoma 1486Lymphoma, T-Cell, Cutaneous 313Skin Neoplasms 267Keratosis, Actinic 249Mycosis Fungoides 224Sezary Syndrome 216Lymphoma, Non-Hodgkin 206Leukemia, Lymphocytic, Chronic, B-Cell 200Lymphoma, Large B-Cell, Diffuse 198Lymphoma, Follicular 196Neoplasms 194Precursor Cell Lymphoblastic Leukemia-Lymphoma 192Lymphoma, B-Cell, Marginal Zone 192Lymphoma, Mantle-Cell 191Hodgkin Disease 191Carcinoma, Basal Cell 190Breast Neoplasms 185Burkitt Lymphoma 184Lymphoma 182Lymphoma, Large-Cell, Immunoblastic 177Carcinoma, Non-Small-Cell Lung 150Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 140Lymphoma, Large-Cell, Anaplastic 137Multiple Myeloma 133Carcinoma, Renal Cell 128Immunoblastic Lymphadenopathy 126Uveal Melanoma 125Neoplasm Metastasis 120Leukemia, Myeloid, Acute 113Waldenstrom Macroglobulinemia 103

Interventions

poly ICLC 1Poly I-C 1Monatide (IMS 3015) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinogenesis × Dermatologic × Clear all
NCT01079741 2018-02-13

Safety Study of Adjuvant Vaccine to Treat Melanoma Patients

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
34 enrolled 10 charts
Dermatologic

Melanoma, Neoplasms, Skin Neoplasms, Carcinogenesis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡